You are here: Industry Insights > Acceleron

News List

FDA Takes Action for Failure to Submit Required Clinical Trials Results to Clinicaltrials.gov americanpharmaceuticalreview
April 30, 2021
The FDA has issued its first Notice of Noncompliance to Acceleron Pharma, Inc. (Acceleron) for failing to submit required summary results information to ClinicalTrials.gov.
Acceleron gets EC orphan designation for sotatercept to treat PAH pharmaceutical-business-review
December 17, 2020
Acceleron Pharma has secured orphan designation from the European Commission (EC) for its sotatercept to treat patients with pulmonary arterial hypertension (PAH).
Acceleron receives PRIME designation from EMA for Sotatercept in pulmonary arterial hypertension pharmaceutical-business-review
May 06, 2020
Acceleron Pharma said that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of patients with pulmonary arterial hypertension (PAH).
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia drugs
June 11, 2019
Celgene Corporation and Acceleron Pharma Announce U.S. FDA Accepts Luspatercept Biologics License Application in Myelodysplastic Syndromes and Beta-Thalassemia.
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA drugs
April 11, 2019
Celgene Corporation and Acceleron Pharma Announce Submission of Luspatercept Biologics License Application to U.S. FDA.
Celgene and Acceleron's blood disorder drug smashes endpoints at Phase 3 pharmafile
July 17, 2018
Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming that it demonstrated a “highly statistically significant improvement”
Acceleron Appoints Chief Medical Officer americanpharmaceuticalreview
July 11, 2018
Acceleron Pharma announced the appointment of Robert K. Zeldin, M.D., as Chief Medical Officer (CMO). Dr. Zeldin brings to Acceleron more than two decades of clinical, regulatory and industry experience, most recently serving as CMO of Belgium-based Ablyn
Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia firstwordpharma
July 10, 2018
Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced results from a phase III, randomized, double-blind
New medical chief at Acceleron biospectrumasia
July 09, 2018
Dr. Zeldin succeeds longtime Acceleron CMO, Matthew Sherman, M.D., who earlier this year announced his planned retirement.